CONNECT 1906: PEP-CMV on HGG, DIPG, and MB

Who Can Participate in the Study?

Age Group
Both

Study Details

Full Title
CONNECT 1906: Phase 2 trial of a novel peptide vaccine (PEP-CMV) targeting CMV antigen for newly diagnosed pediatric high-grade glioma (HGG) and diffuse intrinsic pontine glioma (DIPG) and recurrent medulloblastoma (MB).
Principal Investigator
Headshot of Daniel Bryce Landi
Associate Professor of Pediatrics
Protocol Number
IRB: PRO00109336
NCT: NCT05096481
Phase
Phase II
ClinicalTrials.gov
Enrollment Status
OPEN TO ACCRUAL